Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination
Allergy · 2025
DOI: 10.1111/all.16241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Jana Sophia Buhre und 23 weiteren Autor:innen. Beteiligte Einrichtung: Laboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lübeck and University Medical Center Schles…. Hauptthemen laut MEDLINE: Immunoglobulin G, SARS-CoV-2, COVID-19 Vaccines, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Recently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti‐tumor necrosis factor (TNF) treatment leads to impaired vaccine‐induced immune responses and protection against breakthrough infections. However, the effects of TNF blockade on short‐ and long‐term immune responses after repeated vaccination remain unclear. Vaccination studies have shown that initial short‐term IgG antibodies (Abs) carry highly galactosylated and sialylated Fc glycans, whilst long‐term IgG Abs have low levels of galactosylation and sialylation and are most likely generated by long‐lived plasma cells (PCs) derived primarily from the germinal center (GC) response. Thus, IgG Fc glycosylation patterns may be applicable to distinguish short‐ and long‐term vaccine responses after repeated vaccination under the influence of anti‐TNF treatment.
Methods
We used COVID‐19 vaccination as a model to investigate vaccine‐induced IgG subclass levels and Fc glycosylation patterns, B cell subsets, and effector functions of short‐ and long‐term Ab responses after up to three vaccinations in patients on anti‐TNF or other immunosuppressive treatments and in healthy individuals. Using TriNetX, a global healthcare database, we determined the risk of SARS‐CoV‐2 breakthrough infections in vaccinated patients treated with anti‐TNF or other immunosuppressive drugs.
Results
Anti‐TNF treatment reduced the long‐term abundance of all anti‐S IgG subclasses with low levels of galactosylation and sialylation. Re‐activation of potential memory B cells initially generated highly galactosylated and sialylated IgG antibodies, which were progressively reduced after each booster dose in anti‐TNF‐treated patients, especially in the elderly. The reduced short‐ and long‐term IgG (1) levels in anti‐TNF‐treated patients correlated with diminished functional activity and an increased risk for the development of COVID‐19.
Conclusions
The data suggest that anti‐TNF treatment reduces both GC‐dependent long‐lived PCs and GC‐dependent memory B cell‐derived short‐lived PCs, hence both the long‐ and short‐term IgG subclass responses, respectively, after repeated vaccination. We propose that anti‐TNF therapy, especially in the elderly, reduces the benefit of booster vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck, Germany.
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
- Medical Department 1, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Kiel, Germany.
- Laboratory of Anti-viral antibody-omics, TWINCORE-Institute for Experimental Infection Research, Helmholtz Center for Infection Research (HZI) and Medical School Hannover (MHH), Hannover, Germany.
- Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hann…
- Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany.
ORCID-Profile: Johann Rahmöller, Ulrich Kalinke, Yannic C Bartsch, Marc Ehlers
Zitieren
APA
Buhre, J. S., Pongracz, T., Geisen, U. M., Schubert, M., Wang, W., Nouta, J., Obara, M., Lehrian, S., Rahmöller, J., Petry, J., Tran, F., Schreiber, S., Sümbül, M., Berner, D., Gerdes, S., Schirmer, J., Longardt, A. C., Hoff, P., Kalinke, U., …, & Ehlers, M. (2025). Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination. Allergy. https://doi.org/10.1111/all.16241
Vancouver
Buhre JS, Pongracz T, Geisen UM, Schubert M, Wang W, Nouta J, et al. Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination. Allergy. 2025. doi:10.1111/all.16241
BibTeX
@article{Buhre2025,
author = {Buhre, Jana Sophia and Pongracz, Tamas and Geisen, Ulf Martin and Schubert, Mareike and Wang, Wenjun and Nouta, Jan and Obara, Maureen and Lehrian, Selina and Rahmöller, Johann and Petry, Janina and Tran, Florian and Schreiber, Stefan and Sümbül, Melike and Berner, Dennis and Gerdes, Sascha and Schirmer, Jan and Longardt, Ann Carolin and Hoff, Paula and Kalinke, Ulrich and Ludwig, Ralf J and Bartsch, Yannic C and Hoyer, Bimba F and Wuhrer, Manfred and Ehlers, Marc},
title = {Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16241}
}
EUVIMED